Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nucana Plc ADR (NCNA)

Nucana Plc ADR (NCNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 797
  • Shares Outstanding, K 6,077
  • Annual Sales, $ 0 K
  • Annual Income, $ -24,280 K
  • EBIT $ -22 M
  • EBITDA $ -22 M
  • 60-Month Beta 1.25
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.12
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -7.02
  • Most Recent Earnings $-0.63 on 06/02/25
  • Next Earnings Date 06/05/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0346 +257.23%
on 06/02/25
0.2000 -38.20%
on 06/11/25
+0.0798 (+182.19%)
since 05/16/25
3-Month
0.0325 +280.31%
on 05/13/25
1.3400 -90.78%
on 03/28/25
-0.7064 (-85.11%)
since 03/17/25
52-Week
0.0325 +280.31%
on 05/13/25
10.7900 -98.85%
on 08/19/24
-2.8664 (-95.87%)
since 06/17/24

Most Recent Stories

More News
RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks

Shares of Rallybio Corporation RLYB tanked 41.2% on April 8 after the company announced its decision to stop the development of RLYB212 for the prevention of fetal and neonatal alloimmune thrombocytopenia...

FOLD : 5.80 (-4.13%)
RLYB : 0.3380 (-3.98%)
ANIP : 63.35 (-1.46%)
NCNA : 0.1236 (-5.79%)
NuCana plc Reports Encouraging Clinical Data for NUC-7738 and NUC-3373, Highlights Financial Position and Future Milestones

NuCana reported encouraging results for NUC-7738 and NUC-3373 in recent clinical trials, with financial updates and a projected cash runway.Quiver AI SummaryNuCana plc announced encouraging Phase 2 results...

NCNA : 0.1236 (-5.79%)
German Court Rules that Gilead’s Sofosbuvir Infringes NuCana’s ‘190 Patent

EDINBURGH, United Kingdom, July 11, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that, following a comprehensive hearing on May 17, 2022,...

NCNA : 0.1236 (-5.79%)
NuCana Announces Presentation on NUC-7738 at the European Hematology Association (EHA) 2022 Hybrid Congress

NUC-7738 Shows Promising Non-Clinical Activity in Acute Myeloid Leukemia NUC-7738 Kills AML Cells Resistant to Standard Chemotherapy Data Indicates...

NCNA : 0.1236 (-5.79%)
NuCana Announces Receipt of NASDAQ Notice

EDINBURGH, United Kingdom, June 03, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that it received written notification (the “Notification...

NCNA : 0.1236 (-5.79%)
NuCana Reports First Quarter 2022 Financial Results and Provides Business Update

Initiated Randomized Phase 2 Study of NUC-3373 in Patients with Colorectal Cancer Initiated Phase 1b/2 Study of NUC-3373 in Combination with Other...

NCNA : 0.1236 (-5.79%)
NuCana to Participate in the 2022 Jefferies Healthcare Conference

EDINBURGH, United Kingdom, June 01, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Don Munoz, Chief Financial Officer, will host...

NCNA : 0.1236 (-5.79%)
NuCana Reports Fourth Quarter and Year Ended 2021 Financial Results and Provides Business Update

Optimizes Development Strategy with Study Initiations and Data Announcements Expected throughout 2022 Announces Plan to Initiate Randomized Phase 2 Study...

NCNA : 0.1236 (-5.79%)
NuCana Announces Upcoming Presentations on NUC-3373 at the American Association for Cancer Research (AACR) Annual Meeting 2022

Checkpoint Inhibitor Nivolumab Activity Enhanced by NUC-3373 in vitro NUC-3373 Shown to be a More Efficient DNA Damaging Agent in Cancer Cells than 5-FU ...

NCNA : 0.1236 (-5.79%)
NuCana Announces Update for Phase 3 Biliary Tract Cancer Study

Independent Data Monitoring Committee Recommended Study be Discontinued Following Futility Assessment Conducted at First Interim Analysis NUC-3373...

NCNA : 0.1236 (-5.79%)

Business Summary

NuCana PLC is a clinical-stage biopharmaceutical company. It focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The company's pipeline of products includes Acelarin, NUC-3373 and NUC-7738 which are in clinical stage. NuCana PLC is based in...

See More

Key Turning Points

3rd Resistance Point 0.1578
2nd Resistance Point 0.1514
1st Resistance Point 0.1413
Last Price 0.1236
1st Support Level 0.1248
2nd Support Level 0.1184
3rd Support Level 0.1083

See More

52-Week High 10.7900
Fibonacci 61.8% 6.6806
Fibonacci 50% 5.4113
Fibonacci 38.2% 4.1419
Last Price 0.1236
52-Week Low 0.0325

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
OSZAR »